All In Biotech

Drug Trial Radar · NCT00920582

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

254

Actual

Start

Sep 2009

Primary completion

Apr 2012

Study completion Jul 2012

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Jun 15, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • Teplizumab Herold RegimenBiological

    Full dose of teplizumab IV for 14 days, repeated at Week 26

  • PlaceboDrug

    IV dosing daily for 14 days repeated at Week 26

  • Teplizumab 33.3% Herold RegimenBiological

    One third full dose of teplizumab IV for 14 days, repeated at Week 26

  • Teplizumab Curtailed Herold RegimenBiological

    Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.Time frame: 52 weeks after randomization
  2. Mean Change From Baseline in HbA1c Between Teplizumab and PlaceboTime frame: 52 weeks after randomization

Locations

118 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • NEA Clinic

    Jonesboro, Arkansas

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Clinical Innovations Inc. Research Facility

    Costa Mesa, California

  • Axis Clinical Trials

    Los Angeles, California

  • Diabetes Associates Medical Group, Inc

    Orange, California

  • Clinical Innovations, Inc.

    Riverside, California

  • San Diego Clinical Trials

    San Diego, California

  • Ronald Chochinov Md Inc

    Ventura, California

  • Yale University

    New Haven, Connecticut

  • Christiana Care Research Institute

    Newark, Delaware

  • Richard Hays, MD

    Wellington, Florida

  • Atlanta Diabetes Associates

    Atlanta, Georgia

  • John H Stoger Jr. Hospital of Cook County, Cook County Hospital

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • Mid-America Diabetes Associates

    Wichita, Kansas

  • St. Agnes Hospital

    Baltimore, Maryland

  • Maryland Diabetes & Endocrine Associates

    Rockville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Alzohaili Medical Consultants

    Dearborn, Michigan

  • Children's Hospitals and Clinics of Minnesota

    Saint Paul, Minnesota

  • University of Missouri - Columbia, Cosmopolitan Diabetes and Endocrinology

    Columbia, Missouri

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • Saint Barnabas Medical Center

    Livingston, New Jersey

  • Albany Medical College

    Albany, New York

  • Bassett Healthcare

    Cooperstown, New York

  • East Carolina University, Brody School of Medicine

    Greenville, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • GHS Pediatric Endocrinology

    Greenville, South Carolina

  • AM Diabetes & Endocrinology Center

    Bartlett, Tennessee

  • University Diabetes & Endocrine Consultants

    Chattanooga, Tennessee

  • LeBonheur Children's Medical Center

    Memphis, Tennessee

  • Research Institute of Dallas

    Dallas, Texas

  • Southwest Clinical Trials

    Houston, Texas

  • Houston Center for Clinical Research

    Houston, Texas

  • Medical & Surgical Clinic of Irving

    Irving, Texas

  • InVisions Consultants, LLC

    San Antonio, Texas

  • Diabetes and Glandular Disease Research Associates, PA

    San Antonio, Texas

  • Endocrine Research Specialists

    Ogden, Utah

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.